扬帆新材 reported revenue of ¥0.46B for the period ended 2026-06-30, -2.3% year on year. Net income was ¥0.01B, a 1.4% net margin on a 18.6% gross margin. The largest revenue line is 巯基化合物及衍生品 at 53% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.46B | -2.3% |
| Gross profit | ¥0.09B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -71.3% |
| Gross margin | 18.6% | Net margin 1.4% |
| Revenue Q/Q | +27.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 巯基化合物及衍生品 | ¥0.24B | 52.6% |
| 光引发剂 | ¥0.12B | 26.8% |
| 其他 | ¥0.10B | 20.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 81.4% |
| R&D | ¥0.02B | 4.4% |
| SG&A | ¥0.04B | 9.4% |
| Tax & other | ¥0.00B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥1.37B |
| Total liabilities | ¥0.66B |
| Shareholders' equity | ¥0.71B |
| Equity / assets | 52.1% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | 447% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies